Everything below concerns mass confirmation. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid as supplied |
| Water solubility | Soluble | Dissolves in aqueous media |
| Typical storage temperature | -20 °C | Dry powder, desiccated, protected from light |
| Typical analytical method | RP-HPLC with mass spectrometry | Purity from peak area; mass for identity |
| Common synonyms | Tβ4 fragment; thymosin beta-4 fragment | Naming varies by supplier and catalogue |
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
== Medical uses == Cryoneuralysis has been used to relieve pain after thoracotomy, mastectomy, and knee or shoulder arthroplasty. Combined with ultrasound imaging, the procedure can be administered using a hand-held device in an office, and appears to provide an expedient, safe, and nonpharmacological option for treating various chronic pain conditions.
If consuming recovery drink after a workout, to maximize muscle protein anabolism, it is suggested that the recovery drink contain glucose (dextrose), protein (usually whey) hydrolysate containing mainly dipeptides and tripeptides, and leucine.
In Buddhism, the Dharma Chakra is widely used to represent the Buddha's Dharma (Buddha's teaching and the universal moral order), Gautama Buddha himself and the walking of the path to enlightenment, since the time of Early Buddhism. The symbol is also sometimes connected to the Four Noble Truths, the Noble Eightfold Path and Dependent Origination. The pre-Buddhist dharmachakra (Pali: dhammacakka) is considered one of the ashtamangala (auspicious signs) in Hinduism and Buddhism and often used as a symbol of both faiths. It is one of the oldest known Indian symbols found in Indian art, appearing with the first surviving post-Indus Valley Civilisation Indian iconography in the time of the Buddhist king Ashoka. The Buddha is said to have set the "wheel of dharma" in motion when he delivered his first sermon, which is described in the Dhammacakkappavattana Sutta. This "turning of the wheel" signifies a great and revolutionary change with universal consequences, brought about by an exceptional human being. Buddhism adopted the wheel as a symbol from the Indian mythical idea of the ideal king, called a chakravartin ("wheel-turner", or "universal monarch"), who was said to possess several mythical objects, including the ratana cakka (the ideal wheel). The Mahā Sudassana Sutta of the Digha Nikaya describes this wheel as having a nave (nābhi), a thousand spokes (sahassārāni) and a felly (nemi), all of which are perfect in every respect.
A downside of NFT is that it has very little buffering against interruptions in the flow (e.g., power outages). But, overall, it is probably one of the more productive techniques. The same design characteristics apply to all conventional NFT systems. While slopes along channels of 1:100 have been recommended, in practice it is difficult to build a base for channels that is sufficiently true to enable nutrient films to flow without ponding in locally depressed areas. As a consequence, it is recommended that slopes of 1:30 to 1:40 are used. This allows for minor irregularities in the surface, but, even with these slopes, ponding and water logging may occur. The slope may be provided by the floor, benches or racks may hold the channels and provide the required slope. Both methods are used and depend on local requirements, often determined by the site and crop requirements. For nutrient film technique (NFT) systems, recommended flow rates are commonly around 1 L/min per gully to provide sufficient nutrient replenishment to the root film. At planting, rates may be half this and the upper limit of 2 L/min appears about the maximum. Flow rates beyond these extremes are often associated with nutritional problems. Depressed growth rates of many crops have been observed when channels exceed 12 meters in length. On rapidly growing crops, tests have indicated that, while oxygen levels remain adequate, nitrogen may be depleted over the length of the gully. As a consequence, channel length should not exceed 10–15 meters.
=== Early life and education === Baker was born into a Jewish family in Seattle, Washington on October 6, 1962, the son of physicist Marshall Baker and geophysicist Marcia (née Bourgin) Baker. He graduated from Seattle's Garfield High School. Baker received a Bachelor of Arts degree with a major in biology from Harvard University in 1984. He then joined the laboratory of Randy Schekman, where he worked primarily on protein transport and trafficking in yeast, and obtained a Doctor of Philosophy in biochemistry from the University of California, Berkeley in 1989. In 1993, he completed his postdoctoral training in biophysics with David Agard at the University of California, San Francisco.
Sources: en.wikipedia.org
Hence, the perception is that both disseminated HS and MH follow a rapid clinical progression despite therapeutic intervention. This is certainly true once clinical signs are apparent, but the subclinical period is of unknown duration. The HS complex of diseases is best recognized in the Bernese Mountain Dog in which a familial association is apparent. Other breeds are predisposed to HS complex diseases and include Rottweilers, Golden Retrievers, and Flat-coated Retrievers. Although HS complex is not limited to just these breeds and can occur sporadically in any breed. Primary lesions of HS occur in spleen, lymph node, lung, bone marrow, skin and subcutis especially of extremities. Secondary sites are widespread, but consistently include liver and lung (with splenic primary), and hilar lymph node (with lung primary). Clinical signs include anorexia, weight loss, and lethargy. Other signs depend on the organs involved and are a consequence of destructive mass formation. Accordingly, pulmonary symptoms such as cough and dyspnea have been seen. CNS involvement (primary or secondary) can lead to seizures, incoordination and paralysis. Regenerative and non-regenerative anemia have been consistently documented in hemophagocytic HS. Lameness is often observed in periarticular HS. Treatment of HS complex Localized HS affecting skin and subcutis have been cured by early surgical excision.
== Brand names == Brand names for Oxymetazoline include Afrin, ClariClear, Dristan, Drixine, Drixoral, Nasivin, Nasivion, Nezeril, Nostrilla, Logicin, Vicks Sinex, Visine L.R., Sudafed OM, Otrivin, Oxy, SinuFrin, Vicks Sinex Severe (Spray), and Mucinex Sinus-Max. A topical cream formulation is sold under the brand name Rhofade. Oxymetazoline ophthalmic solution for the treatment of acquired blepharoptosis is marketed as Upneeq. In the United Arab Emirates, oxymetazoline nasal sprays are sold under imported brand names such as Otrivin. The UAE does not manufacture oxymetazoline but domestic pharmaceutical companies such as Julphar produce xylometazoline, a structurally related imidazoline decongestant.
Codex Alimentarius Codex Alimentarius General Standard for Irradiated Foods (CAC/STAN 106-1983, rev.1 2003) at the Wayback Machine (archived 2007-09-26) Codex Alimentarius Recommended International Code of Practice Code for Radiation Processing of Foods (CAC/RCP 19-1979, rev.2 – 2003) Archived October 5, 2021, at the Wayback Machine General Standard for the Labelling of Prepacked Foods (CODEX STAN 1-1985) Archived April 6, 2011, at the Wayback Machine Food Irradiation Processing Alliance FIPA represents the irradiation service industry, manufacturers of food irradiators and suppliers of cobalt-60 sources. Irradiation of Food and Food Packaging at the Wayback Machine (archived 2009-03-04), Center for Food Safety and Applied Nutrition (US Government) Facts about Food Irradiation at the Wayback Machine (archived 2006-03-16), a series of 14 fact sheets, International Consultative Group on Food Irradiation, International Atomic Energy Agency, Vienna, 1991 Bibliography on Food Irradiation Archived May 3, 2006, at the Wayback Machine, Federal Research Centre for Nutrition and Food, Karlsruhe, Germany IAEA interactive map of irradiation facilities Archived April 20, 2021, at the Wayback Machine Keener, Kevin M. "Department of Food Science Food Irradiation: To Zap or not to Zap?" (PDF). North Carolina State University. Archived from the original (PDF) on September 7, 2015. Retrieved January 12, 2021.
Charlemagne founded the Carolingian Empire in 800; it was divided in 843. The eastern successor kingdom of East Francia stretched from the Rhine in the west to the Elbe river in the east and from the North Sea to the Alps. Subsequently, the Kingdom of Germany and the Holy Roman Empire emerged from it. The Ottonian rulers (919–1024) consolidated several major duchies. In 996, Gregory V became the first German Pope, appointed by his cousin Otto III, whom he shortly after crowned Holy Roman Emperor. The Holy Roman Empire absorbed northern Italy and Burgundy under the Salian emperors (1024–1125), although the emperors lost power through the Investiture Controversy. Under the Hohenstaufen emperors (1138–1254), German princes encouraged German settlement to the south and east (Ostsiedlung). Members of the Hanseatic League, mostly north German towns, prospered in the expansion of trade. The population declined starting with the Great Famine in 1315, followed by the Black Death of 1348–1350. The Golden Bull issued in 1356 provided the constitutional structure of the Empire and codified the election of the emperor by seven prince-electors. Johannes Gutenberg introduced moveable-type printing to Europe, laying the basis for the democratisation of knowledge. Following Martin Luther's 1517 Protestant Reformation, bolstered by his standardised Bible translation, led to the 1555 Peace of Augsburg, which recognised Lutheranism under the principle of cuius regio, eius religio (ruler's faith dictates subjects' faith).
=== Communication === Communication is a vital part of the diagnostic process. The Internist uses both synchronous and asynchronous communication with other members of the medical care team, including other internists, radiologists, specialists, and laboratory technicians. Tools to evaluate teamwork exist and have been employed in multiple settings. Communication to the patient is also important to ensure there is informed consent and shared decision-making throughout the diagnostic process.
Sources: en.wikipedia.org
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.
The parent protein contains forty-three amino acids, while the fragment carries only a short motif from one region. The fragment can interact with actin in vitro, but it does not include the rest of the protein structure. Whether the shorter molecule behaves the same way in living systems is not settled.
Published controlled human studies are scarce, and most activity reports come from cell culture or animal models. Reviews often describe the evidence base as limited and methodologically uneven. Open questions include the relationship between route, dose, and measured outcomes.
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.